TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06367985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Oxygen Concentration CAPA-IVM culture
Description: * Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Oxygen Concentration CAPA-IVM culture
Description: * Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius.
Study: NCT06225037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedline EEG with output concealed
Description: Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
Study: NCT04659096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION537
Description: ION537 will be administered by IV injection.
Study: NCT04920825

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sacha Inchi Oil softgel supplement
Description: A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil softgel
Description: A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
Study: NCT04831619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)
Description: A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
Study: NCT06480461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R09b
Description: This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R09b
Description: This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
Study: NCT05831540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT06480461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R09b
Description: This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
Study: NCT06011824

Intervention type: OTHER
Intervention: Blood draw
Description: 10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)

Intervention type: OTHER
Intervention: Blood draw
Description: 10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)

Intervention type: OTHER
Intervention: Blood draw
Description: 10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)

Intervention type: OTHER
Intervention: Blood draw
Description: 10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
Study: NCT06048588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YN001
Description: In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for YN001
Description: The injection solution to mimic the YN001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin calcium tablets
Description: In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
Study: NCT06599073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RescueDoppler
Description: Continuous hands-free Doppler ultrasound of the carotid artery during cardiac arrest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rescue
Description: RescueDoppler patch with probe is attached on the left side of the neck during the cardiac arrest. Operative health personell are blinded for the velocity curves that are post-processed by the research team after the cardiac arrest and synchronised with ECG.
Study: NCT04846868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin
Description: Iclepertin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05293314

Intervention type: DIAGNOSTIC_TEST
Intervention: An exhaled breath test
Description: All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: An exhaled breath test
Description: All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: An exhaled breath test
Description: All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.
Study: NCT05059522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral
Study: NCT05374083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using autogenous demineralized dentin block graft
Description: Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by hydrochloric acid (HCL) acid and inserted as demineralized dentin block graft in the socket

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using particulate deproteinized bovine bone graft
Description: Atraumatic extraction of non restorable tooth, then the socket will be packed by particulate deproteinized bovine bone
Study: NCT06479395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Endurance and Limb Strengthening (PEDALS) program
Description: Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-Oriented Training (TOT)
Description: The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
Study: NCT06438627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC combined with Apatinib and Camrelizumab
Description: Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP Combined With Camrelizumab
Description: Gemcitabine, Cisplatin regimen Combined With Camrelizumab
Study: NCT06396390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin
Description: In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
Study: NCT06126419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Insulin Therapy
Description: A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is \> mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Insulin Therapy
Description: A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is \> mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
Study: NCT06140420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Oral Product
Description: Generic, oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT05711329

Intervention type: OTHER
Intervention: Accuracy
Description: We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).
Study: NCT05644210

Intervention type: DRUG
Intervention: Telitacicept
Description: 160mg once a week for 24 weeks

Intervention type: DRUG
Intervention: Rituximab
Description: Patients received 200mg of rituximab intravenously at week 0 and week 2.

Intervention type: DRUG
Intervention: Rituximab
Description: Patients received 200mg of rituximab intravenously at week 0 and week 2.

Intervention type: DRUG
Intervention: Aspirin
Description: 50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Aspirin
Description: 50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
Study: NCT06171048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection
Study: NCT05644210

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: 200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: 200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period

Intervention type: DRUG
Intervention: Prednisone
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Prednisone
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Study: NCT05059522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatanib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV (intravenous) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: oral
Study: NCT05563077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity interval training (MIIT)
Description: MIIT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period (∼6-7 reps of 4 min at ∼4.2 METs, with 3 min of active recovery at ∼2.2 METs between each interval), and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs). We will select the same aerobic dose of training (i.e., kcal/kg of body weight per week) to match total energy expenditure in both exercise groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Description: MICT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period at ∼3.2 METs, and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs).
Study: NCT04893330

Intervention type: DIETARY_SUPPLEMENT
Intervention: pepticate syneo
Description: follow up of pepticate syneo for one month
Study: NCT05059522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP 001
Description: IT (intratumoral) or SC (subcutaneous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04518600
Description: IV infusion
Study: NCT05319951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Salts power (iii)
Description: Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with white granulated sugar
Description: Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
Study: NCT05632133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 MG Oral Tablet
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
Study: NCT05592470

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Description: Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Description: Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
Study: NCT04840654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Block
Description: form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure.
Study: NCT05851846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amygdala insula retraining
Description: Mind body intrevention
Study: NCT05845164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (\</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS Sham
Description: EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons.
Study: NCT06164795

Intervention type: DRUG
Intervention: Zoledronate
Description: intravenous infusion

Intervention type: DRUG
Intervention: Zoledronate
Description: intravenous infusion

Intervention type: DRUG
Intervention: Denosumab
Description: subcutaneous injection